Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B
The German biotech will partner with Genentech, part of the Roche Group, to develop targeted…
The German biotech will partner with Genentech, part of the Roche Group, to develop targeted…
Update: Following on from earlier approvals in the US, the European Commission announced it has given…
Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M),…
Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR…
TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation…
The FDA has approved the use of Novartis' CAR-T therapy Kymriah in adult patients with…
Novartis' Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in…
Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in…
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has…
Despite all the hype, CRISPR is still not in the clinic as a standalone therapy…
Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that…